The facility will initially manufacture medications in vial form, with future plans to produce sterile injectables in syringes. This is the first U.S. FDA approval for the Indore facility.

The site is expected to eventually produce medicines in syringes, in addition to vials. This is the Indore facility's first US FDA approval. Endo plans to apply for additional product approvals at the ...

TOKYO -- Japan is not making progress in vaccinations against the HPV, which causes cervical cancer. As of January 2024, the HPV vaccine had been introduced into national immunization programs in ...